STOCK TITAN

Lemaitre Vascular Inc - LMAT STOCK NEWS

Welcome to our dedicated news page for Lemaitre Vascular (Ticker: LMAT), a resource for investors and traders seeking the latest updates and insights on Lemaitre Vascular.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lemaitre Vascular's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lemaitre Vascular's position in the market.

Rhea-AI Summary
LeMaitre Vascular, Inc. (LMAT) will announce its first quarter 2024 financial results on May 2, 2024, after the market close. A conference call is scheduled for 5:00 PM ET the same day to discuss business highlights and outlook.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
LeMaitre Vascular, Inc. (LMAT) CFO to present at Needham Virtual Healthcare Conference. JJ Pellegrino to discuss company's financial outlook.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
conferences
-
Rhea-AI Summary
LeMaitre Vascular, Inc. (LMAT) will participate in four investor conferences in March 2024, including Oppenheimer Healthcare MedTech & Services Conference, Barclays Global Healthcare Conference, Roth Conference, and KeyBanc Life Sciences & MedTech Investor Forum.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
conferences
News
Rhea-AI Summary
LeMaitre (LMAT) reports strong Q4 2023 results with a 19% sales increase, $0.16/share dividend, and positive guidance for 2024. Key financial highlights include a 46% growth in operating income, a 50% increase in net income, and a 49% rise in diluted EPS. The company's gross margin improved to 68.1%, driven by higher selling prices and operational efficiencies. LeMaitre also announced a share repurchase program and a quarterly dividend of $0.16/share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.41%
Tags
-
Rhea-AI Summary
LeMaitre Vascular, Inc. (LMAT) is set to announce its fourth quarter 2023 financial results on February 27, 2024, with a conference call scheduled to discuss the results, business highlights, and company outlook.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.24%
Tags
-
Rhea-AI Summary
LeMaitre Vascular, Inc. (Nasdaq:LMAT) CFO to Present at 26th Annual Needham Growth Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
conferences
Rhea-AI Summary
LeMaitre Vascular, Inc. (Nasdaq:LMAT) will be participating in three upcoming investor conferences in November. The conferences include Jefferies London Healthcare Conference on November 14 in London, UK, where the Chief Financial Officer will present at 11:00 AM GMT. Stifel's 2023 Healthcare Conference will also take place on November 14 in New York City, with the President presenting at 1:50 PM ET. Lastly, the Piper Sandler 35th Annual Healthcare Conference will be held on November 29 in New York City, where the President will present at 2:10 PM ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
Rhea-AI Summary
LeMaitre (Nasdaq:LMAT) reported Q3 2023 results with sales of $47.4mm, a 21% increase from Q3 2022. Gross margin increased to 65.0%. Operating income grew by 49% to $9.2mm. Net income was $7.5mm, a 38% increase. The company announced a $0.14/share quarterly dividend. Q4 2023 guidance projects sales of $48.0mm - $50.0mm and operating income of $9.4mm - $10.7mm.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.45%
Tags
-
Rhea-AI Summary
LeMaitre Vascular to release Q3 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
Rhea-AI Summary
LeMaitre Vascular, Inc. to present at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
conferences
Lemaitre Vascular Inc

Nasdaq:LMAT

LMAT Rankings

LMAT Stock Data

1.44B
20.03M
10.21%
91.35%
3.47%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Burlington

About LMAT

lemaitre vascular is a provider of devices and implants for the treatment of peripheral vascular disease, a condition that affects more than 20 million people worldwide. the company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. the company's diversified product portfolio consists of brand name devices used in arteries and veins outside of the heart. the company is listed on nasdaq.